© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Before the 1990s, doctors had to make tough calls in treating tricky infections. Sometimes, the drugs just weren't strong enough or bacteria fought back. Pazufloxacin mesylate popped up in Japan as part of the quest for stronger tools against tough bugs, especially when hospitals noticed rising numbers in resistant bacteria. It rose from dedicated pharmaceutical minds who saw gaps in the range of fluoroquinolones then available. The teams involved wanted something with a wider kill zone against bacteria, safe enough for hospital use. The Japanese regulatory agencies approved it in the late 1990s, after researchers showed that pazufloxacin could handle cases where other drugs fumbled. Over time, it’s reached clinics in Asia, especially for severe and hospital-acquired infections like complicated urinary and respiratory cases. Its story grows out of straight-up practical need: fight bacteria that just won’t quit.
Pazufloxacin mesylate comes as a powder or solution, controlled tightly due to its specific spectrum and hospital-focused role. Typical vials hold doses tailored for direct intravenous drip. In the hospital setting, nurses and pharmacists handle it with care, avoiding wide distribution to curb resistance. Only patients actually needing this high-tier antibiotic get it. Prescribers tend to keep it on reserve, rolling it out mostly when infections refuse to budge after standard treatments. Drugmakers market it under several names, the best known being “Pazucross” in Japan, reflecting its purpose—bridging gaps where other antibiotics fail.
Pazufloxacin under a microscope looks like a white or off-white powder. It doesn’t pack much smell. Technically, it lands firmly in the fluoroquinolone family, built on a bicyclic core structure. Under normal hospital storage (cool and dry), the powder remains stable in a vial for months. Solutions need to be used pretty quickly after preparation since light and air start breaking the molecule down. Solubility stands as one positive feature—mixes well enough in water for intravenous use, sparing hospitals from headaches over clogging or mixing troubles. The chemical formula—C15H14FN3O3, mesylate salt—anchors those in the pharmacy world needing to verify authenticity.
Hospitals usually pick up pazufloxacin in specified 250 mg or 500 mg vials, labeled for strict intravenous use. Labels carry the manufacturer’s name, batch, expiration, and directions for proper dilution—crucial for patient safety and medication tracking. The instructions ride along on clear, no-nonsense leaflets. All technical documents stress incompatibility with a few common minerals and avoid mixing in the same line with drugs containing calcium, to sidestep precipitation risks. Labels and literature in Asia often carry both generic and trade names, along with cautious language around renal function because clearance mainly relies on kidney performance. Drug interactions with theophylline or non-steroidal anti-inflammatory drugs come flagged in red, based on observed risks for side effects.
Drug manufacturers cook up pazufloxacin mesylate through a multi-step organic synthesis, adding mesylate for improved water solubility. Preparation at bedside stays straightforward: open the vial, draw up correct saline amount—usually 100 ml—and dissolve the powder gently. Hospital pharmacists warn never to shake too hard since froth can make dosing tricky. After mixing, the solution gets used right away, minimizing chance of chemical breakdown. Sterile technique matters every time—the drug goes straight into veins. Anything leftover gets logged and disposed of as per medical waste laws. Nurses trained in hospital antibiotic protocols juggle timing of administration with other treatments, given pazufloxacin’s specific interaction profile.
Chemists building pazufloxacin start with a base quinolone scaffold, then tack on a fluorine atom to boost antibacterial punch. The mesylate modification shifts water solubility, a must-have for intravenous forms. There’s constant curiosity in labs about tweaking positions on the core structure, especially since one small change may tilt the spectrum of activity. Research outfits, particularly in Japan and China, keep exploring how minor modifications open the door to even broader infection coverage or tweak resistance patterns. These chemical nips and tucks mainly stay out of the clinical spotlight until new versions meet strict toxicity and effectiveness hurdles.
You may run into pazufloxacin mesylate labeled as Pazucross, PZFX, or simply pazufloxacin injection in hospital supply lists. The full chemical mouthful—(S)-(+)-1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid monomethanesulfonate—never shows up in patient handouts. Pharmacists rely on both international and local generic lists to avoid mix-ups with other quinolones that have nearly identical names. This attention to precise nomenclature keeps patient charts and pharmacy logs in line—critical to avoid errors, especially with antibiotics that sit so close together on the shelf.
Strict hospital rules surround pazufloxacin mesylate: only trained pharmacists prep the medicine, only IV administration, and all leftovers designated hazardous waste. Healthcare professionals keep tabs on kidney function and known allergy history before giving a dose. During infusions, nurses look out for any sign of rash, unexplained pain, or neurological symptoms. Cases of confusion or tendon soreness reported with other fluoroquinolones often prompt quick intervention. Hospitals want to avoid steering bugs toward resistance, so antibiotic stewardship teams monitor usage patterns—reserving the drug for the times it’s most needed. Labels mark out exact storage: room temperature, dry, out of light. Routine audits check inventory to halt expired product from landing in patient care areas.
Hospital wards and intensive care units form the usual home for this medicine. Pazufloxacin sees duty in treating difficult bacterial infections, mostly severe community-acquired or hospital-acquired cases such as pneumonia, complicated urinary tract infections, and abdominal infections—places where patients have already failed standard first-line treatments. Surgeons and infectious disease doctors may request it after seeing cultures come back resistant to safer or more common drugs. Its utility stands strongest in settings where doctors weigh the risk of resistance and only turn to it for verified multi-drug resistant bacteria. Pazufloxacin rarely sticks around for routine infections because risks outweigh benefits in milder cases.
Drug development didn’t stop after the first batch reached hospitals. Trials in Asia keep testing pazufloxacin against the evolving roster of bacterial threats. Scientists track resistance genes, constantly measuring how bugs like Klebsiella and Pseudomonas react. Clinical researchers in the last decade shared data comparing pazufloxacin to other intravenous agents, often considering mortality rates, cure speed, and side effects like kidney strain. Studies showed pazufloxacin fills a needed niche, but teams pay close attention to resistance signals—something hospitals everywhere dread. Drug manufacturers keep nudging chemical structures to widen reach, but always under strict regulation and safety checks set by national agencies. The pace of research ramps up every time bacteria find ways around existing therapy, driving another cycle of re-examination.
Toxicity always sits top-of-mind for high-powered antibiotics. Lab tests in rats and dogs found dose-related effects on kidneys and sometimes nervous tissue. Early warning signs—tremors, gait changes, or changes in urine output—guided dosing recommendations now found in the prescribing literature. Clinics require kidney monitoring, especially in patients with underlying renal issues, before and during use. Real-world experience showed similar side effect patterns to the rest of the fluoroquinolone family, with rare but real risks of tendon injury or central nervous system changes. Post-marketing surveillance keeps scooping up both common and rare adverse events. Regulators expect routine data flow from hospitals back to drugmakers—part of the deal to keep these antibiotics on shelves for emergencies.
Looking ahead, pazufloxacin’s fate rides on two main rails: emerging resistance and clinical safety. If bacteria keep getting craftier, even last-resort drugs like this could find themselves outgunned. Research continues on possible oral forms, hoping to expand access beyond the ICU. Many public health officials push for tight stewardship, knowing unrestricted use would shrink its usefulness. Cheminformatics experts and biotechs keep sketching analogs in hope that minor tweaks will either extend the life of pazufloxacin or lead to even tougher next-gen compounds. Academic labs eye promising combo regimens where antibiotics support each other to slow resistance. For now, pazufloxacin stays an essential hospital backstop—used only when doctors run out of options, with all hands vigilant for both miraculous recoveries and signs of resistance on the horizon.
I’ve come across all sorts of antibiotics, but few names spark as much curiosity as Pazufloxacin Mesylate. Doctors prescribe this medication for tough bacterial infections that don't respond well to older drugs. It belongs to the fluoroquinolone family, which is known for powerful action against a wide range of bacteria. Hospitals rely on agents like this, especially where quick recovery often means everything for the patient’s outcome.
Life inside a hospital exposes patients to infectious threats you just don’t worry about elsewhere. Pneumonia, especially the kind acquired inside hospital walls, has changed the game. These bacterial strains often resist conventional treatments. In my experience supporting families during hospital stays, I’ve seen that a delayed response can lead to longer stays and even fatal outcomes. Pazufloxacin Mesylate helps clinicians mount a stronger defense where other therapies fail. It has shown success against organisms like Pseudomonas aeruginosa and Acinetobacter, which are notorious for dodging most antibiotics.
Some might hope new drugs like Pazufloxacin Mesylate will stamp out infections for good, but medicine doesn’t work that way. Bacterial resistance grows with overuse, and antibiotics can carry real risks. For example, fluoroquinolones have gotten a reputation for side effects such as tendon issues or impacts on the central nervous system. Anyone familiar with modern prescribing policies will tell you: doctors tend to use medications like these when they have strong reasons, not for common colds or mild infections. Otherwise, the next generation of bacteria find new tricks to survive.
Most prescriptions for Pazufloxacin Mesylate come out of East Asian countries, such as Japan and China, where the drug has approval and regular supply. In many Western countries, you’ll notice the absence of this drug in routine hospital protocols, mainly because authorities require more data or rely on other medicines. This patchwork in access makes clear that clinicians must keep multiple options available, adjusting based on local resistance patterns and available evidence. That approach fits with the advice I’ve heard echoed in infectious disease circles: treat bacteria based on local realities, not just textbooks.
Antibiotic stewardship stands out as central to using Pazufloxacin Mesylate responsibly. Hospitals put systems in place for monitoring how drugs get prescribed, catching inappropriate use before resistance springs up. Experts recommend continuing education for healthcare providers so that every script for drugs like this comes with a real plan—right bacteria, right dose, right duration. A friend of mine working in infection control says the conversation always circles back to accountability: if one group misuses a potent medication, the broader community pays the price through more resistant bugs down the line.
As bacteria keep evolving, both research and daily practice adjust. Clinical trials collect outcome data, and every case feeds into a bigger picture. The presence of Pazufloxacin Mesylate in pharmacy shelves carries some comfort for patients facing serious infections. Still, its real value shines through coordinated efforts from doctors, pharmacists, and patients, applying the newest knowledge and avoiding shortcuts. Only then can important antibiotics like this keep making a difference where it counts.
Pazufloxacin mesylate comes into the conversation for treating tough bacterial infections, especially when other antibiotics fall short. Doctors rely on it in hospitals, particularly for conditions such as pneumonia and urinary tract infections caused by germs that don’t surrender easily. While the drug works for many, there’s a real need to recognize how it can affect people, especially if they take it for several days or combine it with other treatments. This isn’t just about a list of possible issues; it’s about making sure those who use the medicine get the relief they need without unexpected harm.
Nausea, stomach pain, and diarrhea often show up for patients. These symptoms reflect how antibiotics not only target dangerous bacteria but also disrupt the healthy bacteria that live in the gut. Over years of practice, I’ve seen most people struggle with mild digestive problems, but complaints fade after a day or so. Still, the discomfort doesn’t help people who are already feeling run down, and the temptation to stop the pills early can creep in. Sticking with the course matters, though, because half-treated infections don’t go quietly—they tend to bounce back, sometimes worse than before.
The real trouble starts when the body’s chemistry clashes with the medication. Allergic reactions keep doctors on high alert. Rashes, swelling, shortness of breath, or hives appear as red flags. Prompt care can make all the difference in these moments. In rare but serious cases, pazufloxacin can affect the liver. I remember a patient who developed yellowish skin and dark urine during treatment; lab work uncovered rising liver enzymes. He recovered, but the experience highlights the reason regular monitoring matters. Kidney function also deserves a watchful eye, since damage can develop without warning. Doctors rely on repeat lab tests to catch these changes early.
Repeated use of antibiotics nudges bacteria to find ways to outsmart treatment, a reality well known by clinicians. Overusing powerful drugs like pazufloxacin contributes to the rise of resistant superbugs—bacteria that refuse to budge for even the toughest medicines. This development doesn’t just affect individuals; it endangers the wider community. I have seen wards where, over time, options shrink and more aggressive drugs become routine. Cutting back on unnecessary prescriptions, reserving pazufloxacin for infections with no better alternative, slows this dangerous trend.
Responsibility doesn’t rest only on doctors. Patients must speak up about allergies and other medications. Taking the drug with food can take the edge off stomach upset, based on feedback from those I’ve treated. Patients should report any yellowing of the eyes, severe abdominal pain, or persistent rashes without delay. For healthcare professionals, clear instructions and routine checks on bloodwork form the backbone of safe antibiotic use. Educating families on how and when to use complex antibiotics like pazufloxacin shields both individual and public health. Informed decisions make all the difference in avoiding preventable harm.
Honest conversation about benefits and risks forms the foundation of good care. Pazufloxacin mesylate can change the course of infection, but people need to know what it can do to the body along the way. Open dialogue backed by clinical experience and scientific evidence respects the knowledge patients bring about their own lives. In medicine, sharing real facts and options always works better than hiding worries behind technical language. The right information, presented in plain terms, empowers people to use treatments wisely and safely.
Pazufloxacin mesylate sits in the class of quinolone antibiotics, often stepping in when a tough infection resists older drugs. Treading through medical literature makes it clear: this isn’t an antibiotic to handle on your own. Hospitals lean on it for conditions like pneumonia or urinary tract infections that spark fever or complications. Doctors don’t hand it out for the routine cough or sniffle.
Pazufloxacin gets administered through an intravenous drip. I remember sitting in on a hospital round; nurses carefully set up the IV bags, ensuring everything stays sterile. Dripping too fast risks side effects, including changes in blood pressure. Too slow, and the drug won’t reach its targets in time. Each dose gets calculated based on the patient’s weight, kidney function, and the severity of the infection. Kidneys clear pazufloxacin from the body, so labs check creatinine and adjust the dose for anyone with kidney disease. Skipping this step exposes patients to danger: too much drug means higher risk for mental changes or tendon trouble, both linked to this class of antibiotics. I’ve never seen a trustworthy prescriber handpicking doses without a close look at kidney numbers.
Doctors order the infusion typically twice per day, spaced out enough for consistent blood levels. You can’t just “set it and forget it;” hospital teams track progress, watching for improvement in symptoms and side effects. I’ve seen people turn the corner quickly—relief that comes as both a comfort and a reminder to finish the full prescribed days, not just until feeling better. Quitting early only raises the odds for drug-resistant bacteria. Patients often want to leave early out of frustration; education makes a real difference in sticking with the plan.
Drug connections demand real attention. Pazufloxacin can clash with drugs for seizures, diabetes, or even over-the-counter antacids. Teams run thorough medication reviews. Those with allergies to other quinolones steer clear; a bad reaction in the past spells higher risk this time around.
Hydration also plays a role. Hospital protocols nudge patients to drink water (if possible), preventing dehydration and helping kidneys flush the drug. Signs like confusion, muscle pain, or skin rashes demand quick reporting, not waiting things out. One missed symptom could unravel a whole treatment plan.
Pazufloxacin doesn’t work as a cure-all. Strong antibiotics like this one serve best under a guiding hand—specialists who know when to use them and when to hold off. Hospitals set up guidelines for its use, reviewing each case and gathering feedback on results. If resistance patterns shift or a side effect turns up more often, protocols change. My respect for this careful, measured approach only grows as I see the downstream effects of careless prescriptions. Responsible administration keeps people safer for the long haul.
Pazufloxacin mesylate belongs to the fluoroquinolone family. Doctors in some countries turn to it for tough bacterial infections, like complicated urinary tract or respiratory issues. This drug steps up when common antibiotics fall short, but that power comes with responsibility—both for doctors and patients.
No drug exists in a bubble. Even if a medicine is effective on its own, mixing it with others can produce surprising and sometimes dangerous effects. People with experience managing chronic health problems quickly learn that drug interactions shape everyday routines. With fluoroquinolones like pazufloxacin, the stakes are real.
For example, magnesium or aluminum-based antacids can tie up fluoroquinolones in the gut, cutting the amount that makes it into the bloodstream. I’ve seen patients who take antacids faithfully, yet their infection lingers because the antibiotic just isn’t being absorbed. That’s frustrating for everyone involved, and it can mean longer time spent feeling sick.
On the flip side, nonsteroidal anti-inflammatory drugs (NSAIDs)—think ibuprofen—can bump up a person’s risk of nervous system side effects like confusion or tremors when paired with certain fluoroquinolones. Mixing medicines without guidance isn’t harmless. Clinical studies back up these concerns, showing a real uptick in problems when NSAIDs and fluoroquinolones are combined.
Warfarin, a blood thinner prescribed to prevent clots, interacts with a long list of drugs, including some antibiotics. Reports show fluoroquinolones can boost warfarin’s blood-thinning effects, raising the odds of unexpected bleeding. Doctors need to keep an eye on lab markers like INR when patients take both medicines together. Missing these details could lead to serious trouble—a lesson learned the hard way by more than one healthcare team.
Other medicines, like diabetes drugs, don’t play well with some fluoroquinolones. Blood sugar swings can catch both doctors and patients off guard. The U.S. FDA has flagged these issues, urging caution for patients using blood sugar medication with antibiotics in this family.
Of all the lessons from treating people with complex medication regimens, the most important is to treat the whole person, not just the infection. Missed interactions don’t just add up on a list—they show up in the ER, the doctor’s office, or truly tough moments at home.
Taking time before starting a new prescription to run all current medicines through a pharmacist’s database matters. Family members can help by bringing all bottles—prescription and non-prescription—to medical appointments. Digital health records help catch problems if the whole care team stays in communication.
Drug manufacturers and regulatory agencies keep lists updated, but new medicines land on shelves each year, and new interactions crop up. Keeping up means making room for ongoing education and real conversations about side effects and risks. No one benefits from keeping quiet or guessing.
The safest path with pazufloxacin, and antibiotics in general, involves openness between everyone—doctor, pharmacist, and patient. That’s what keeps powerful drugs helpful, not harmful.
Pazufloxacin mesylate falls into the class of fluoroquinolone antibiotics. It fights tough bacterial infections that resist older treatments. Hospitals in parts of Asia use it to tackle pneumonia, urinary tract infections, and intra-abdominal infections. As antibiotic resistance grows, doctors sometimes turn to newer drugs like pazufloxacin when tried-and-true options fall short.
Most doctors agree: drug safety during pregnancy and breastfeeding often involves more uncertainty than confidence. Pregnant bodies carry more than one life, so any pill swallowed deserves close scrutiny. With pazufloxacin, human studies don’t exist to confidently answer the question, “Will this drug harm an unborn baby?” Animal studies paint a troubling picture. Rats and rabbits given high doses developed skeletal problems in their offspring. That rings alarm bells because a baby’s bones form and mineralize throughout pregnancy. Fluoroquinolones, as a class, sometimes weaken cartilage in developing joints. Decades of research on their relatives—drugs like ciprofloxacin—show similar signals.
Signs point toward caution rather than trust. When looking through regulatory guidance from the Japanese Pharmaceuticals and Medical Devices Agency, pazufloxacin gets flagged for use in pregnancy only if other drugs can’t cut it. The U.S. Food and Drug Administration doesn’t currently approve this antibiotic, but if it did, the warning would run the same: avoid or reserve for emergencies.
It’s not just about pregnancy. Nursing mothers transfer what they take in through their milk. No one knows how much pazufloxacin shows up in breast milk. Other fluoroquinolones do pass through to some degree. In newborns, even a small amount could do damage—either by upsetting gut flora or by affecting bone development. So far, healthcare organizations like the American Academy of Pediatrics haven’t given pazufloxacin a green or even a yellow light for nursing mothers. Many breastfeeding specialists view most fluoroquinolones with suspicion, and stick with antibiotics that have decades of safety data.
Doctors must balance the immediate dangers of an infection with the longer-term risks to baby and parent. No parent wants to risk a preventable infection spreading unchecked. In cases where standard antibiotics fail, doctors sometimes reach for pazufloxacin as a last line. Even then, the risks get discussed openly. This isn’t a drug anyone prescribes lightly.
Alternative antibiotics—like penicillins or cephalosporins—carry stronger safety records in pregnancy and breastfeeding. If infection control demands a fluoroquinolone, medical teams often consult infectious disease specialists and pharmacists. Hospital ethics boards may even review tough cases.
Science moves slowly, but the lack of pregnancy and breastfeeding data for new antibiotics deserves attention. Drug companies could fund reproductive safety studies before new antibiotics receive widespread use. Public health agencies might follow up on real-world use to catch problems early. Right now, most patients and their doctors make choices in a data fog—a risky place for growing families.
It’s tough to ask for patience with infections raging. But for anyone who dreams of safe pregnancies and healthy newborns, pressures to cut corners with untested drugs can backfire. Until more information arrives, the wise path sticks with older antibiotics whenever possible and brings specialists into the conversation for the rare exceptions.
| Names | |
| Preferred IUPAC name | 4-Quinolin-6-yl-3,7-dihydro-8-methyl-6-oxo-2-(1H-tetrazol-5-yl)-1H-pyrazolo[4,3-c]quinoline-1-carboxylic acid, methanesulfonate (1:1) |
| Other names |
PZFX Pazucross Pazu Pazufloxacin |
| Pronunciation | /paˌzuːflɒkˈsæsɪn ˈmɛsɪleɪt/ |
| Identifiers | |
| CAS Number | [127045-41-4] |
| Beilstein Reference | 18749518 |
| ChEBI | CHEBI:75266 |
| ChEMBL | CHEMBL2106034 |
| ChemSpider | 184657 |
| DrugBank | DB12710 |
| ECHA InfoCard | 100000011377 |
| EC Number | 62055-05-4 |
| Gmelin Reference | 904661 |
| KEGG | D05359 |
| MeSH | D017045 |
| PubChem CID | 124089 |
| RTECS number | GV8990000 |
| UNII | T23H9U4B7N |
| UN number | UN2527 |
| CompTox Dashboard (EPA) | Pazufloxacin Mesylate CompTox Dashboard (EPA) string: **DTXSID3059249** |
| Properties | |
| Chemical formula | C16H15FN4O3·CH4O3S |
| Molar mass | 473.50 g/mol |
| Appearance | white or pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.78 g/cm3 |
| Solubility in water | Soluble in water |
| log P | -0.64 |
| Acidity (pKa) | 8.15 |
| Basicity (pKb) | 8.66 |
| Magnetic susceptibility (χ) | -73.0e-6 cm³/mol |
| Refractive index (nD) | 1.629 |
| Viscosity | Not less than 90% (of the labeled amount) |
| Dipole moment | 3.2±0.5 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Pazufloxacin Mesylate is 635.8 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | J01MA10 |
| Hazards | |
| Main hazards | May cause allergic reactions, gastrointestinal disturbances, central nervous system effects, and photosensitivity. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07, GHS09 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. Read label before use. If medical advice is needed, have product container or label at hand. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: – |
| Flash point | > 270.2 °C |
| Lethal dose or concentration | LD50 mouse (iv): 639 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse i.v. 621 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 1500 mg/day |
| Related compounds | |
| Related compounds |
Pazufloxacin Pefloxacin Ciprofloxacin Ofloxacin Levofloxacin Norfloxacin |
